We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Drug Discovery Services Market: Growth, Size, Share, and Trends

Report Code PH 5682
Published in Mar, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030

Overview

The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a CAGR of 10.7%. Growing R&D expenditure from drug pharmaceutical and biopharmaceutical companies, the increasing R&D pipeline creating a need for increased analytical testing outsourcing, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are contributing to market growth. In addition, technological advancements, the development of new drug discovery techniques, the expiration of patents, and the increasing demand for specialized testing services among end users present further avenues for growth.

Key segments positively impacting the market include chemistry services, with the largest share dominant due to technologies such as combinatorial chemistry and structure-based drug design. In the therapeutic area, the oncology segment commanded the highest market share. Pharmaceutical and biotechnology companies are the largest end users, owing to high research & development investments.

Drug Discovery Services Market

Attractive Opportunities in the Drug Discovery Services Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the rising government spending and increasing therapeutic area expertise.

The rising number of agreements, partnerships, and collaborations among market players are fueling market growth.

Growing awareness about personalized medicines and targeted therapies, a vast patient population, and emerging middle-class population are enhancing market penetration in the Asia Pacific region.

The Asia Pacific drug discovery services market is expected to grow at a CAGR of 13.0% during the forecast period.

Stringent regulations are likely to negatively impact market growth.

Global Drug Discovery Services Market Dynamics

DRIVER: Growing research & development expenditure in pharma-biotech sector

The increasing R&D investments by pharmaceutical and biopharmaceutical companies are driving fully integrated or functional outsourcing for drug discovery and development from early to late phases. With the pressure to reduce fixed costs, outsourcing has become a strategic approach to address the lack of in-house resources for product development. Large pharma companies are moving to leaner business models that heavily depend on outsourcing. Many companies outsource R&D testing functions to increase profitability, meet drug development timelines, and reduce costs. Recent partnerships between large pharma companies and CROs offering drug discovery and development services are driving the drug discovery services market growth.

RESTRAINT: Stringent regulations

Ensuring drug safety and efficacy is a priority for regulatory bodies during approval. While these measures ensure product quality, they also increase drug development and final product cost. In cost-sensitive emerging markets, this can impact the adoption of certain drugs. Compliance with GMP regulations raises manufacturing costs. As per Thermo Fisher Scientific Inc., the approval process of the FDA (standard, fast track, breakthrough, accelerated approval, or priority review) depends on the importance and necessity of the drug, making it more complex for developers.

 

OPPORTUNITY: Rising demand for specialized testing services

Traditionally, pharmaceutical, biopharmaceutical, and medical device companies conducted early-phase method development projects and problem-solving activities in-house. They only outsourced late-phase drug development and routine processes. However, partnering earlier in drug development to create efficiencies has been a growing trend in recent years. Companies are increasingly outsourcing specialized testing services such as liquid chromatography-mass spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, trace metal analysis with inductively coupled mass spectrometry (ICP-MS), and various others much earlier in the API process development cycle. These specialized services are mainly used for structural elucidation of key impurities, removing class I and II solvents, hazard analysis, removal of column chromatography, and efforts toward overall cost reduction and process efficiency. The tests require high-end equipment and skilled professionals. To save on the cost of equipment and labor, pharmaceutical and biopharmaceutical companies prefer to outsource these specialized testing services to CROs. For instance, companies such as Pfizer, Merck, and Roche have reduced their in-house testing services to fuel their R&D pipelines and meet the growing demand for new drug molecules for various therapeutic areas.

CHALLENGES: Economic uncertainties worldwide

The drug discovery services witnessed a downfall in 2023 and 2024 owing to cuts in funding for pharma R&D and economic uncertainties around the world. Economic uncertainties persist as a challenge for the drug discovery services market, impacting funding, operations, and workforce stability. The economic slowdown has also weakened the funding cycle, so venture capital funding has declined for emerging biotech firms. Inflation and energy prices, in addition to currency volatility, have significantly strained company budgets and delayed drug discovery timelines. While a few companies began to turn to strategies such as outsourcing to CROs or utilizing digital technologies to optimize costs, the pressures on the market continued, disrupting the broader challenges of geopolitical and economic instability. These challenges further highlight the demand for the resilience and adaptability of the drug discovery sector, with widening work on advanced technologies such as AI and automation to drive costs down and maintain operational continuity.

Global Drug Discovery Services Market Ecosystem Analysis

The drug discovery services market functions within an ecosystem that includes various stakeholders. Many interconnected stakeholders play an important role in each new drug discovery process. This ecosystem includes suppliers of raw materials, service providers, end users, and regulatory bodies working together to ensure the successful discovery of safe and effective drugs. The market includes various types of academic institutions that conduct early-phase research to aid drug commercialization for drug companies. Regulatory bodies, along with CROs, help to ensure that the process follows security and efficacy standards. Key market players are established companies operating in drug discovery services for several years, boasting extensive service portfolios and robust global sales and marketing networks.

Drug Discovery Services Market
 

The hit-to-lead identification segment dominated the market in 2024.

Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. The growth of hit-to-lead identification services can be attributed to their vital role in drug discovery, as it is the most revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.

The cardiovascular diseases segment dominated the market in 2024.

The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The cardiovascular diseases segment dominated the market owing to the high prevalence of cardiovascular diseases, the rising geriatric population, and the increasing partnerships between CROs and pharmaceutical & biotechnology companies. Innovation in genetics and personalized medicine, which will be integrated into the discovery and development of cardiovascular disease therapeutics, will also help the growth of this market segment.

 

North America held the largest share of the drug discovery services market in 2024.

The drug discovery services market is divided by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the global drug discovery services market and is projected to maintain that share in the forecast period. Within North America, the US holds a dominant position due to the presence of major CROs. Its focus on R&D expenditure and rapid growth in the biosimilar and biologics markets also fuels the demand for drug discovery services. The US is a global hub for drug discovery and development. Most drug development research is conducted with a well-defined regulatory system and well-established service providers with advanced R&D infrastructure in the country. The US is the largest pharmaceutical market worldwide and a global leader in pharmaceutical and biopharmaceutical research.

According to the WHO, clinical trials conducted in the US were 5,999 in 2024. This is mainly due to the increasing number of cancer patients in the country and the significant R&D spending by pharmaceutical and biopharmaceutical companies to develop novel cancer drugs. The US is also the world's largest pharmaceutical market and a global leader in pharmaceutical and biopharmaceutical research. According to Statista, as of 2024, 39% of companies involved in pharmaceutical R&D are based in the US. Almost all large pharmaceutical companies, including Bristol-Myers Squibb (US), Merck (US), Johnson & Johnson (US), and Eli Lilly (US), have a strong presence in the US and are engaged in drug R&D. This, along with the rising R&D expenditure and clinical trials, makes the US an attractive market for CROs focusing on drug discovery activities. The strong and growing contract service industry in the US is also driving the market growth. It ensures rapid access to the required drug discovery services and contributes to the pace of R&D activity. This expands the drug discovery services market.

Drug Discovery Services Market
HIGHEST CAGR MARKET IN 2025-2030
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of Drug Discovery Services Market

  • In January 2025, Charles River Laboratories (US) collaborated with NJ Bio, Inc. (US), a contract research organization focused on integrated chemistry and bioconjugation services, toward assisting clients in advancing antibody drug conjugate (ADC) development from concept to clinic. The partnership combines the end-to-end ADC discovery capabilities of Charles River Laboratories with the biologic conjugation and manufacturing expertise of NJ Bio, Inc.
  • In September 2024, Labcorp (US) expanded the Greenfield facility to enable the proposition and scientific proof of concept of pre-clinical and clinical molecular bioanalytical tests used in the qualifications of product substances related to advanced medicines, cell & gene therapies, and cancer-induced rare diseases, among others.
  • In May 2024, WuXi AppTec (China) announced a site for the new R&D and manufacturing site in Singapore to support customers globally in healthcare treatment and innovation.
  • In April 2024, Aurigene Pharmaceutical Services Ltd. (India) announced the launch of AI and machine learning (ML) capabilities to assist in speeding up drug discovery projects from hit identification to candidate selection at Pharmaceutical Services Limited (India).
  • In February 2024, Eurofins Scientific (France) launched DiscoveryAI SAFIRE (a Suite of ADMET Predictions for In Silico Refinement and Evaluation). SAFIRE is a state-of-the-art platform that utilizes proprietary datasets, artificial intelligence (AI), and machine learning (ML) methodology, creating novel capabilities for accelerating drug discovery.
  • In February 2024, Charles River Laboratories (US) partnered with Wheeler Bio (US) to build the CMC platform to address discovery and safety assessment.

Key Market Players

Want to explore hidden markets that can drive new revenue in Drug Discovery Services Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Products & Service, Application and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Key Questions Addressed by the Report

Who are the key players in the drug discovery services market?
The key players in the drug discovery services market are Thermo Fisher Scientific Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), and Labcorp (US), among others.
Which process segment dominates the drug discovery services market?
The hit-to-lead identification segment dominated the market in 2024.
Which type segment dominates the drug discovery services market?
The chemistry services segment dominated the market in 2024.
Which drug type segment dominates the drug discovery services market?
The small molecules segment dominated the market in 2024.
Which therapeutic area segment of the drug discovery services market is expected to register the highest growth?
The cardiovascular diseases segment is anticipated to register the highest CAGR during the forecast period.
What is the size of the drug discovery services market?
The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025.
At what rate is the drug discovery services market growing?
The global drug discovery services market is expected to grow at a CAGR of 10.7%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
56
EXECUTIVE SUMMARY
76
PREMIUM INSIGHTS
89
MARKET OVERVIEW
97
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
    TRENDS
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
  • 5.4 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS OF SERVICE, 2024
    INDICATIVE PRICING ANALYSIS OF SERVICE, BY REGION, 2024
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - HIGH-THROUGHPUT SCREENING (HTS)
    - CRISPR GENE EDITING
    - STRUCTURE-BASED DRUG DESIGN/COMPUTER AIDED DRUG DESIGN (CADD)
    COMPLEMENTARY TECHNOLOGIES
    - AUTOMATED LIQUID HANDLING
    - IN SILICO MODELING
    - PATIENT-DERIVED XENOGRAFTS (PDX MODELS)/ORGANOIDS
    ADJACENT TECHNOLOGIES
    - NANOTECHNOLOGY
    - SYNTHETIC BIOLOGY
    - ORGAN-ON-A-CHIP TECHNOLOGY
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.11 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITION RIVALRY
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/ GEN AI ON DRUG DISCOVERY SERVICES MARKET
DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030
115
  • 6.1 INTRODUCTION
  • 6.2 TARGET SELECTION
  • 6.3 TARGET VALIDATION
  • 6.4 HIT TO LEAD IDENTIFICATION
  • 6.5 LEAD OPTIMIZATION
  • 6.6 CANDIDATE VALIDATION
DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030
167
  • 7.1 INTRODUCTION
  • 7.2 CHEMISTRY SERVICES
    SYNTHETIC CHEMISTRY SERVICES
    ANALYTICAL CHEMISTRY SERVICES
    OTHER CHEMISTRY SERVICES (PROCESS CHEMISTRY, CHEMICAL PROTEOMICS)
  • 7.3 BIOLOGY SERVICES
    IN VITRO PROFILING SERVICES
    TOXICOLOGY SERVICES
    OTHER BIOLOGY SERVICES (MICROBIOLOGY, IMMUNOLOGY)
DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030
187
  • 8.1 INTRODUCTION
  • 8.2 SMALL MOLECULES
  • 8.3 BIOLOGICS
DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030
207
  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
  • 9.3 INFECTIOUS DISEASES
  • 9.4 CARDIOVASCULAR DISEASES
  • 9.5 NEUROLOGICAL DISEASES
  • 9.6 IMMUNOLOGICAL DISORDERS
  • 9.7 DIGESTIVE AND GASTROINTESTINAL DISEASES
  • 9.8 GENITOURINARY AND WOMEN’S HEALTH
  • 9.9 RESPIRATORY DISEASES
  • 9.10 ENDOCRINE AND METABOLIC DISEASES
  • 9.11 OTHERS THERAPEUTIC AREA (DERMATOLOGY, RARE DISEASES, ORPHAN DISEASES, OPHTHALMOLOGY, MUSCULOSKELETAL DISEASES)
    DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030
DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030
267
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    TIER 1 COMPANIES
    TIER 2 COMPANIES
    TIER 3 COMPANIES
  • 10.3 ACADEMIC RESEARCH INSTITUTES
  • 10.4 OTHER END USERS (CROS, IVD, CLINICAL RESEARCH LABS)
DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023-2030
306
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    UK
    FRANCE
    ITALY
    SPAIN
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    SOUTH KOREA
    AUSTRALIA
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - SAUDI ARABIA
    - UAE
    - REST OF GCC COUNTRIES
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
358
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - PROCESS FOOTPRINT
    - TYPE FOOTPRINT
    - DRUG TYPE FOOTPRINT
    - THERAPEUTIC AREA FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - DETAILED LIST OF KEY STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 12.7 COMPETITIVE SCENARIO
    DEALS
    OTHER DEVELOPMENTS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.9 VENDOR VALUATION AND FINANCIAL METRICS
COMPANY PROFILES*
391
  • 13.1 KEY PLAYERS
    WUXI APPTEC
    EUROFINS SCIENTIFIC
    THERMO FISHER SCIENTIFIC INC.
    LABCORP.
    CHARLES RIVER LABORATORIES
    EVOTEC
    CURIA GLOBAL, INC.
    PHARMARON
    DR. REDDY’S LABORATORIES LTD.
    GENSCRIPT
    PIRAMAL ENTERPRISES LTD.
    JUBILANT PHARMOVA LIMITED
    SYNGENE INTERNATIONAL LIMITED
    FRONTAGE LABS.
    SYGNATURE DISCOVERY
    SHANGHAI MEDICILON INC.
  • 13.2 OTHER PLAYERS
    VIVA BIOTECH
    TCG LIFESCIENCES PRIVATE LIMITED.
    NUVISAN GMBH (ALS LIMITED)
    ARAGEN LIFE SCIENCES LTD.
    SHANGHAI CHEMPARTNER
    SELVITA
    DALTON PHARMA SERVICES
    DOMAINEX
    ONCODESIGN SERVICES
APPENDIX
407
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery services market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery services market, which was further validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Drug Discovery Services Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Drug Discovery Services Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies.

Stakeholders

  • Drug discovery service providers
  • Pharmaceutical and biotechnology companies
  • Academic & Research Institutes
  • Contract Research Organization
  • Market Research and Consulting Firms
  • R&D Centers
  • Researchers and Scientists
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Industry Associations and Professional Societies

Report Objectives

  • To define, describe, and forecast the drug discovery services market by value by process, type, drug type, therapeutic area, end user and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery services market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

 

Previous Versions of this Report

Drug Discovery Services Market Size, Growth by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) & Region - Global Forecasts to 2026

Report Code PH 5682
Published in Mar, 2023, By MarketsandMarkets™

Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026

Report Code PH 5682
Published in Feb, 2022, By MarketsandMarkets™

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

Report Code PH 5682
Published in Sep, 2020, By MarketsandMarkets™

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

Report Code PH 5682
Published in Jan, 2020, By MarketsandMarkets™

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

Report Code PH 5682
Published in Oct, 2017, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Drug Discovery Services Market

DMCA.com Protection Status